Benitec Initiates Patient Enrollment In T Cell HIV Trial
Benitec said that the Phase I study utilises a triple vector which includes one component utilising Benitec’s DNA-directed RNA interference technology, along with two other proprietary RNA technologies
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.